Oruka Therapeutics (ORKA) PT Raised to $130 at UBS as Stock Undervalued
Tweet Send to a Friend
UBS analyst Michael Yee raised the price target on Oruka Therapeutics (NASDAQ: ORKA) to $130.00 (from $100.00) while maintaining a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
